Sam Fazeli

Has that happened yet?

Or do you expect it to happen?

I think you're the only person who's put a positive spin on that because most people put a negative spin on it saying you want to be in biotech you've got to be in the Boston cluster or the San Francisco cluster because everything is there and everybody's there all the expertise is there.

I mean that makes some sense but I think you're the first person who's actually put a positive spin on the fact that Europe is for want of a better phrase fragmented because it's different countries essentially despite the European Union

is actually an element of it that's positive, but you need to be able to leverage that, which is what I think you're talking about.

Antoine, we've talked for half an hour.

It feels like five minutes, but that's normal.

I mean, I remember this sensation.

Let's just finish on this by asking you, where have you been surprised by the application of AI in the world of drug development and medicine?

And where have you been disappointed?

Just a couple, if I'm just putting you on the spot now, because that wasn't one of my questions.

Let's talk about the current sentiment and sector views, etc.

So what is your, or Safinova's, overarching industry thesis at the moment?

There is turmoil.

One day we see FDA doing strange things when it comes to, we are going to put a black box on vaccines.

We're not going to put a black box on vaccines.

We're

with where the data hasn't been shared.

The next day, I see something that really excites me.

They give a priority voucher to Johnson & Johnson's Majestic 3 trial, which showed an enormous overall survival benefit over already a great success with CAR T's in multiple myeloma.